Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) CEO Michael T. Andriole sold 7,370 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Chimerix Price Performance
Shares of CMRX stock traded up $0.63 during trading hours on Tuesday, reaching $5.01. The company had a trading volume of 3,011,590 shares, compared to its average volume of 1,506,324. The company has a 50 day moving average of $3.60 and a 200 day moving average of $1.85. The firm has a market cap of $450.15 million, a price-to-earnings ratio of -5.33 and a beta of 0.35. Chimerix, Inc. has a 1-year low of $0.75 and a 1-year high of $5.12.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Chimerix in a research note on Monday, December 30th. Wedbush reissued an "outperform" rating and issued a $6.00 price target on shares of Chimerix in a research note on Tuesday, December 10th.
Get Our Latest Analysis on CMRX
Institutional Trading of Chimerix
Several hedge funds have recently added to or reduced their stakes in CMRX. Deerfield Management Company L.P. Series C acquired a new stake in Chimerix during the 4th quarter worth $13,124,000. Rosalind Advisors Inc. bought a new position in Chimerix during the 4th quarter worth about $10,614,000. Boxer Capital Management LLC bought a new position in Chimerix during the 4th quarter worth about $7,169,000. Marshall Wace LLP increased its holdings in Chimerix by 1,318.5% during the 4th quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company's stock worth $7,705,000 after purchasing an additional 2,057,864 shares in the last quarter. Finally, Peapod Lane Capital LLC bought a new position in Chimerix during the 4th quarter worth about $2,626,000. Institutional investors and hedge funds own 45.42% of the company's stock.
About Chimerix
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Featured Stories
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
